cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
=== Symbiosis === Symbionts are the primary providers of nutrition for Osedax. However, these symbionts also possess genes, secretion systems, and toxins that disrupt the Osedax membrane and facilitate recurrent infections of adult Osedax through the root tips. There is ongoing debate in the literature over whether the symbiosis in Osedax roots is commensal or mutualistic. The symbiotic relationship between Osedax and its accompanying bacteria may be transferred either via vertical or horizontal transmission. Osedax species use collagen, which is the primary organic component in bone. Collagen is degraded using a family of endopeptidases called matrix metalloproteinases (MMPs), which facilitates nutrient absorption by the Osedax. The roots of the Osedax express high amounts of V-ATPase and carbonic anhydrase enzymes, which allows the Osedax to dissolve and absorb collagen and lipids. Once dissolved, the nutrients are either used by the Osedax, or transported to the symbionts for further catabolism. As the endosymbionts lack secreted M9 peptidase, they rely on the Osedax worm to source extracellular collagen. The symbionts in the Oceanospirillales order have then been observed to further process the collagen using collagenolytic enzymes. Sequencing of the Osedax worm genome has suggested an evolved dependency on its endosymbionts. This is revealed by genomic streamlining, where increased functional groups were observed despite the loss of some gene families. Six incomplete pathways were discovered in the Osedax worm genome which were supplemented by the endosymbionts.
The last scene of the commercial showed Ivana asking for the last slice, to which Donald replied, "Actually, you're only entitled to half", a play on the couple's recent divorce. In 1995, Ringo Starr appeared in a Pizza Hut commercial that teased to a Beatles reunion, but featured three members of the Monkees. A commercial with Rush Limbaugh dates from the same year, in which he boasts "nobody is more right than me", yet he states for the first time he will do something wrong, which was to participate in Pizza Hut's then "eating pizza crust first" campaign regarding their stuffed crust pizzas. In 1999, the announcer says, "The best pizzas under one roof" in the Big New Yorker pizza commercial seen on the PlayStation Pizza Hut Demo Disc 1. Also, in 1999, the game Crazy Taxi for the Dreamcast featured Pizza Hut as one of the locations to which players were able to drive and drop off customers. However, in the game's 2010 re-release for Xbox Live and PlayStation Network, all of the product placement, including the Pizza Hut locations, were removed and replaced with generic locations. Early 2007 had Pizza Hut move into several more interactive ways of marketing to the consumer. Using mobile-phone SMS technology and their MyHut ordering site, they aired several television commercials (commencing just before the Super Bowl) containing hidden words that viewers could type into their phones to receive coupons.
== Medical uses == In the US, galcanezumab is indicated in adults for the preventive treatment of migraine; and for the treatment of episodic cluster headache. In the EU, galcanezumab is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month.
Sources: en.wikipedia.org
=== Types of surgical incision === To realise the emplacement of a prosthetic breast (saline-solution or silicone-gel) into the implant-pocket of the woman patient, plastic surgeons employ five types of surgical incision:
== Career and research == Her first position was at the Allan Memorial Institute of Psychiatry (associated with McGill University). In 1952, she joined the staff of the National Institute for Medical Research (NIMR) where she served as head of the division of Immunology from 1976 to 1988. During that time, she worked extensively with fellow immunologist John H. Humphrey to establish the immunology divisions. Askonas focused on B cells and determined their role in producing antibodies as part of the immune response. At the NIMR she began researching the biosynthesis of polypeptides in milk proteins discovering that the peptides were synthesised from amino acids rapidly in one piece. From 1955 to 1959 she studied the sites of antibody formation using radioactivity to develop our understanding of antibody molecules and the cells of the immune system. From 1959 to 1961 she studied plasma cell tumors as models for antibody formation. She went on to investigate macrophages and their role in antigen presentation (1962–1968). From 1963 to 1966 she studied the fate of antigen in relation to antibody formation and later continued her study of B cells from 1965 to 1970. She wrote several biographies of high-profile scientists, including Niels Kaj Jerne, César Milstein and John Herbert Humphrey. Askonas conducted a filmed interview with Stanley Peart as a segment of what became the Medical Sciences Video Archive housed in the special collections of the library at Oxford Brookes University.
The concept of emission and transmission tomography was introduced by David E. Kuhl, Luke Chapman and Roy Edwards in the late 1950s. Their work would lead to the design and construction of several tomographic instruments at Washington University School of Medicine and later at the University of Pennsylvania. In the 1960s and 70s tomographic imaging instruments and techniques were further developed by Michel Ter-Pogossian, Michael E. Phelps, Edward J. Hoffman and others at Washington University School of Medicine. Work by Gordon Brownell, Charles Burnham and their associates at the Massachusetts General Hospital beginning in the 1950s contributed significantly to the development of PET technology and included the first demonstration of annihilation radiation for medical imaging. Their innovations, including the use of light pipes and volumetric analysis, have been important in the deployment of PET imaging. In 1961, James Robertson and his associates at Brookhaven National Laboratory built the first single-plane PET scan, nicknamed the "head-shrinker". One of the factors most responsible for the acceptance of positron imaging was the development of radiopharmaceuticals. In particular, the development of labeled 2-fluorodeoxy-D-glucose (FDG—firstly synthethized and described by two Czech scientists from Charles University in Prague in 1968) by the Brookhaven group under the direction of Al Wolf and Joanna Fowler was a major factor in expanding the scope of PET imaging.
Sources: en.wikipedia.org
In oncology, in situ is applied in the context of carcinoma in situ (CIS), a term describing abnormal cells confined to their original location without invasion of surrounding tissue. The earliest known use of the term dates back to 1932 in the writing of U.S. surgical pathologist Albert C. Broders, who introduced both the term and the concept. The concept of CIS was initially controversial. CIS is a critical term in early cancer diagnosis, as it signifies a non-invasive stage, allowing for more targeted interventions such as localized excision or monitoring—before potential progression to invasive cancer. Melanoma in situ is an early, localized form of melanoma (a type of malignant skin cancer). In this stage, the cancerous melanocytes (the pigment-producing cells that give skin its color) are confined to the epidermis, the outermost layer of the skin; the melanoma has not yet penetrated into the deeper dermal layers or metastasized to other parts of the body. Beyond oncology, in situ is used in fields where maintaining natural anatomical or physiological positions is essential. In orthopedic surgery, the term refers to procedures that preserve the natural alignment or position of bones or joints. For example, orthopedic plates or screws may be placed without altering the bone's original structure, as in "[the patient] was treated operatively with an in situ cannulated hip screw fixation". In cardiothoracic surgery, in situ often describes techniques where blood vessels are utilized in their original anatomical position for surgical purposes.
After harnessing fire, humans discovered other forms of energy. The earliest known use of wind power is the sailing ship; the earliest record of a ship under sail is that of a Nile boat dating to around 7,000 BCE. From prehistoric times, Egyptians likely used the power of the annual flooding of the Nile to irrigate their lands, gradually learning to regulate much of it through purposely built irrigation channels and "catch" basins. The ancient Sumerians in Mesopotamia used a complex system of canals and levees to divert water from the Tigris and Euphrates rivers for irrigation. Archaeologists estimate that the wheel was invented independently and concurrently in Mesopotamia (in present-day Iraq), the Northern Caucasus (Maykop culture), and Central Europe. Time estimates range from 5,500 to 3,000 BCE, with most experts putting it closer to 4,000 BCE. The oldest artifacts with drawings depicting wheeled carts date from about 3,500 BCE. More recently, the oldest-known wooden wheel in the world as of 2024 was found in the Ljubljana Marsh of Slovenia; Austrian experts have established that the wheel is between 5,100 and 5,350 years old. The invention of the wheel revolutionized trade and war. It did not take long to discover that wheeled wagons could be used to carry heavy loads. The ancient Sumerians used a potter's wheel and may have invented it. A stone pottery wheel found in the city-state of Ur dates to around 3,429 BCE, and even older fragments of wheel-thrown pottery have been found in the same area.
=== 19th century === Originally a farmer from Iowa, Abner Hackleman arrived as the first European American settler in 1845. Taking up a land claim for himself, Hackleman asked Hiram N. Smead to hold another for him until his son arrived from Iowa. In 1846, a year after arriving in Oregon, Hackleman died while returning to Iowa to fetch his family. In 1847 a pair of brothers, Walter and Thomas Monteith, settled in the area, after traveling by ox team along the Oregon Trail from their native state of New York. They were a family of early prominence in the area; in 1848, they bought a claim of 320 acres (1.3 km2) from Hiram Smead for $400 and a horse; they plotted out 60 acres (240,000 m2) for the town site. They named the city "Albany" after their hometown of Albany in New York. During the same period, Hackleman's son Abram reached his father's original land claim and built a log house in an oak grove still known as Hackleman's Grove. He later built a house, which still stands at the corner of Fifth and Jackson. The small settlement that formed on the Hackleman land became known as the community of Takenah in 1849.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.